TrialThe Journal of infectious diseases2023

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.

Pablo Forte-Soto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.